Abstract
A timed-release derivative of mitomycin C (MMC), agarose bead conjugate (MMC-AB), was synthesized using cyanogen bromide method. MMC was released successively for considerably longer period from MMC-AB in vitro and in vivo after intraperitoneal injection to mice. MMC-AB exhibited almost identical inhibitory effect against growth of Ehrlich ascites carcinoma (EAC) cells to free MMC and less toxicity to ddY mouse than free MMC. Calculated therapeutic index (LD10/ED90) of MMC-AB was two times greater than that of free MMC, suggesting its advantage in cancer chemotherapy. On the life span of EAC bearing ddY mouse, MMC-AB showed almost similar efficiency with that of free MMC but less activity was exhibited against BDF1 mouse transplanted L1210 leukemia.
